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Long-lasting	stem	cell-like	memory	CD8	T	cells	with		
high	“Naïveness”	upon	Yellow	Fever	vaccination				 		
One	Sentence	Summary:	The	Yellow	Fever	vaccine	induces	a	CD8	T	stem	cell-like	memory	subset	that	preserves	a	high	degree	of	“Naïveness”	and	is	stably	maintained	for	over	two	decades	in	humans.		
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Abstract:	1	
	2	 Efficient	and	persisting	immune	memory	is	essential	for	long-term	protection	from	3	 infectious	and	malignant	diseases.	The	Yellow	Fever	(YF)	vaccine	is	a	live-attenuated	virus	4	 that	mediates	life-long	protection,	with	recent	studies	showing	that	the	CD8	T	cell	response	5	 is	particularly	robust.	Yet	limited	data	exists	regarding	the	long-term	CD8	T	cell	response,	6	 with	no	studies	beyond	five	years	post-vaccination.		7	 Hereby,	we	investigated	41	vaccinees,	spanning	0.27	to	35	years	after	vaccination.	YF-8	 specific	CD8	T	cells	were	readily	detected	in	almost	all	donors	(38/41),	with	frequencies	9	 decreasing	with	time.	As	previously	described,	effector	cells	dominated	the	response	early	10	 after	vaccination.	We	detected	a	population	of	Naïve-like	YF-specific	CD8	T	cells	that	was	11	 stably	maintained	for	over	25	years	and	was	capable	of	self-renewal	ex	vivo.	In-depth	12	 analyses	of	markers	and	genome-wide	mRNA	profiling	showed	that	Naïve-like	YF-specific	13	 CD8	T	cells	in	vaccinees:	i)	were	distinct	from	genuine	Naïve	cells	in	unvaccinated	donors	14	 ii)	resembled	the	recently	described	stem	cell-like	memory	subset	(Tscm),	and	iii)	amongst	15	 all	differentiated	subsets,	had	profiles	closest	to	the	Naïve.	Our	findings	reveal	that	CD8	16	 Tscm	are	efficiently	induced	by	a	vaccine	in	humans,	persist	for	decades	and	preserve	a	17	 particularly	high	degree	of	“Naïveness”.	This	supports	YF	vaccination	as	an	optimal	18	 mechanistic	model	for	the	study	of	long-lasting	memory	CD8	T	cells	in	humans.	 	19	
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Main	Text:	20	
	21	
	22	
Introduction	23	
	24	 	25	 Cytotoxic	CD8	T	cells	are	key	to	the	destruction	and	clearance	of	pathological	cells	that	26	 harbor	intracellular	infections	or	aberrant	alterations	such	as	tumors.	Therefore,	CD8	T	27	 cells	are	at	the	center	stage	in	the	design	of	immunotherapeutic	strategies	to	fight	cancer	28	 and	chronic	infectious	diseases.	Compared	to	established	therapies	(chemo-	or	radio-29	 therapies),	a	major	advantage	of	immunotherapy	lies	in	the	“memory”	quality	of	adaptive	30	 immune	responses,	with	potential	for	long-term	and	recall	effects.	Great	efforts	are	ongoing	31	 to	better	understand	the	mechanisms	underlying	the	development	and	long-term	32	 maintenance	of	memory	for	protection	from	disease	(1-5).		33	 	34	 The	study	of	human	(CD8)	T	cell	responses	has	largely	relied	on	anti-viral	responses	to	35	 highly	prevalent	or	medically	relevant	viruses.	These	conventional	references	include	the	36	 lifelong	persisting	herpes	viruses	Cytomegalovirus	(CMV)	and	Epstein-Barr	Virus	(EBV),	37	 the	acute	and	seasonal	Influenza	(Flu)	virus,	and	chronic	viruses	that	cause	severe	38	 pathology	such	as	Hepatitis	C	Virus	(HCV)	and	Human	Immunodeficiency	Virus	(HIV)	(6).	39	 For	instance,	the	“CEF”	(CMV,	EBV,	Flu)	peptide	pool	is	amongst	the	most	frequently	used	40	 positive	controls	to	monitor	human	CD8	T	cells	(7).	However,	these	viral	specificities	41	 correspond	to	infections	that	are	difficult	to	track	in	terms	of	the	timing	of	the	exposure	to	42	 the	pathogen,	including	recurrence	in	the	case	of	chronic	infections.	Conversely,	active	43	
		 4	
vaccination	offers	a	scenario	of	synchronized	and	supervised	induction	of	the	immune	44	 response.	As	such,	vaccines	represent,	in	practice,	the	best	available	models	for	the	45	 controlled	study	of	an	immune	response	in	humans	(8).		46	 	47	 While	prevention	of	infection	per	se	is	primarily	guaranteed	by	the	induction	of	48	 neutralizing	antibodies,	the	cytotoxic	CD8	T	cell	responses	are	of	particular	importance	in	49	 the	clearance	of	pathogens	(9).	Several	vaccines,	and	in	particular	live	attenuated	formulae	50	 such	as	the	Yellow	Fever	(YF)	and	Smallpox	vaccines,	induce	robust	T	cell	responses	51	 considered	as	major	contributors	to	the	protection	conferred	by	vaccination	(8,	10).	The	52	 live	attenuated	YF	vaccine	(YF-17D	and	YF-17DD	strains)	stands	out	as	one	of	the	most	53	 successful	in	terms	of	public	health	impact,	as	well	as	the	robustness	and	quality	of	the	54	 immune	response	elicited	(8,	10,	11).	In	use	since	1937,	the	vaccine	is	known	to	induce	55	 neutralizing	antibodies	that	persist	at	least	up	to	38	years	(12).	In	recent	years,	the	YF-17D	56	 vaccine	has	also	attracted	major	research	interest	for	its	capacity	to	induce	a	particularly	57	 strong	CD8	T	cell	response.	This	response	features	high	magnitude,	broad	specificity	with	58	 overlapping	epitopes	spanning	multiple	HLA	class	I	and	class	II	motifs	(conferring	59	 prevalent	and	high	immunogenicity	in	the	human	population),	polyfunctionality,	high	60	 proliferative	potential	and	long-term	persistence	(13-16).	In	addition,	the	particular	innate	61	 response	to	the	live	attenuated	virus	may	contribute	to	the	success	of	the	YF	vaccine,	62	 featuring	the	activation	of	multiple	dendritic	cell	subsets	via	several	pattern	recognition	63	 receptors	to	orchestrate	such	a	competent	adaptive	immune	response	(17-19).	64	 	65	 Upon	vaccination,	there	is	a	peak	of	viremia	that	resolves	by	day	15.	The	CD8	T	cell	66	 response	peaks	between	14	and	30	days	and	can	reach	up	to	10%	of	the	circulating	CD8	T	67	 cells	even	for	a	single	specificity	such	as	the	NS4b214-222	epitope	(13,	15,	16).	In	terms	of	the	68	
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differentiation	phenotype,	YF-specific	CD8	T	cells	show	an	effector	phenotype	(CCR7-	69	 CD45RA-)	very	early	in	the	response	(day	14).	However,	CD45RA	is	re-expressed	from	day	70	 30	onwards	(13,	16,	20).	This	EMRA	population	shows	properties	of	polyfunctional	71	 memory	cells	(CD28+/-,	CD27+,	proliferation),	which	defies	the	conventional	classification	72	 of	EMRA	(CCR7-	CD45RA+)	as	terminally	differentiated	effector	CD8	T	cells	(10,	13,	16).	73	 	74	 In	the	light	of	these	recent	reports,	it	has	become	apparent	that	YF	vaccination	induces	a	75	 distinct	activation	and	memory	differentiation	of	human	CD8	T	cells	that	may	explain	its	76	 particular	efficacy.	However,	reports	so	far	have	addressed	the	phenotype	of	YF-specific	77	 CD8	T	cells	with	particular	emphasis	in	the	first	90	days	after	vaccine	administration,	and	78	 very	limited	data	exists	at	later	time-points.	The	EMRA	phenotype	for	instance	has	been	79	 observed	in	limited	numbers	of	donors	and	only	up	until	46	months	after	vaccination	(13,	80	 16,	20).	In	this	study,	we	aimed	to	thoroughly	characterize	the	memory	CD8	T	cells	that	81	 persist	in	the	long-term,	in	the	range	of	decades	following	YF	vaccination.	 	82	
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Results	83	 	84	 	85	
The	Yellow	Fever	vaccine	17D	induces	a	Naïve-like	population	of	antigen-86	
experienced	CD8	T	cells	that	is	stably	maintained	over	25	years	87	 	88	 We	studied	a	cohort	of	41	healthy	volunteers	vaccinated	with	YF-17D,	between	3	months	89	 and	35	years	ago,	including	four	individuals	having	received	multiple	vaccines	(table	S1).	In	90	 order	to	detect	YF-specific	CD8	T	cells,	we	used	HLA-A*02	tetramers	to	stain	cells	bearing	a	91	 TCR	specific	for	the	highly	prevalent	NS4b214-222	epitope,	hereafter	referred	as	A2/NS4b	92	 (fig.	1	A)	(13,	14,	16).	A2/NS4b+	CD8	T	cells	were	detected	in	the	large	majority	of	93	 vaccinees,	with	only	3	/	41	donors	having	frequencies	below	0.01%	and	considered	94	 negative	(fig.	1	B).	Remarkably,	A2/NS4b+	CD8	T	cells	were	detected	over	at	least	25	years	95	 after	vaccination,	albeit	at	decreasing	frequencies	with	time	(fig.	1	B).		96	 	97	 In	order	to	study	the	differentiation	status	of	YF-specific	CD8	T	cells,	subsets	were	defined	98	 on	the	basis	of	the	expression	of	conventional	markers	CCR7	and	CD45RA,	namely:	Naïve	99	 (CCR7+	CD45RA+),	CM	(CCR7+	CD45RA-),	EM	(CCR7-	CD45RA-)	and	EMRA	(CCR7-	100	 CD45RA+)	subsets	(6),	as	indicated	in	fig.	1C.	A2/NS4b+	CD8	T	cells	showed	considerable	101	 heterogeneity	in	subset	distribution	amongst	donors.	Overall,	only	a	few	donors	showed	102	 substantial	CM	populations,	and	the	largest	proportion	of	cells	were	found	either	in	the	103	 EMRA	subset	or,	surprisingly,	falling	within	the	conventional	Naïve	gate	(fig.	1D	and	E).	We	104	 hereafter	termed	these	CCR7+	CD45RA+	A2/NS4b+	CD8	T	cells	“Naïve-like”,	since	they	105	 appeared	in	the	conventional	Naïve	gate	but	their	“genuine	Naïve	vs	memory”	nature	was	106	 to	be	determined,	as	addressed	throughout	the	experiments	that	follow.	Moreover,	we	107	
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observed	that	these	A2/NS4b+	Naïve-like	CD8	T	cells	displayed	variable	levels	for	CCR7	108	 and	CD45RA.	There	was	either	CCR7high	CD45RAhigh	expression	(hereafter	termed	109	 “Naïvehigh”),	or	intermediate	CCR7	and/or	CD45RA	expression	(hereafter	termed	110	 “Naïveint”).	The	detailed	gating	is	shown	in	fig.	1	C	and	D	and	quantified	in	fig.	1E.						111	 	112	 Next,	we	addressed	the	relationship	between	the	differentiation	status	of	YF-specific	CD8	T	113	 cells	in	relation	to	the	years	since	vaccination.	Of	note,	there	was	an	inherent	trend	towards	114	 longer	vaccine	history	corresponding	to	vaccinees	of	older	age	(fig.	S1	A).	Increasing	age	is	115	 known	to	correlate	with	fewer	Naïve	cells	and	slightly	more	differentiated	cells	116	 (EM/EMRA)	(fig.	S1	B	and	C)	(21,	22).	In	order	to	normalize	inter-donor	and	age-related	117	 variations,	we	quantified	the	frequency	of	A2/NS4b+	CD8	T	cells	within	each	118	 differentiation	subset,	rendering	the	data	independent	of	the	personal	composition	of	119	 subsets	in	Total	CD8	T	cells	as	well	as	independent	of	the	age	of	donors	(fig.	S1	D).		120	 	121	 YF	vaccination	induced	a	large	population	of	differentiated	CD8	T	cells,	comprising	up	to	122	 6.45%	of	EMRA	early	after	vaccination,	that	steadily	decreased	with	time	(fig.	2	A,	panel	123	 “EMRA”;	fig.	2	C,	slope	=	-0.093).	Although	generally	less	frequent,	the	CM	and	EM	124	 populations	detected	also	decreased	with	time	(fig.	2	A,	“EM”	and	“CM”	panels),	but	less	125	 steeply	(fig.	2	C).	Interestingly,	the	population	of	Naïve-like	A2/NS4b+	CD8	T	cells	was	also	126	 clearly	increased	in	vaccinees	compared	to	unvaccinated	individuals,	hinting	that	this	127	 Naïve-like	population	is	mobilized	by	the	vaccine	(fig.	2	A,	“Naïve”	panel).	Yet	most	128	 strikingly,	the	frequency	of	Naïve-like	A2/NS4b+	CD8	T	cells	was	stably	maintained	over	129	 the	years	after	vaccination,	even	after	25	years	(fig.	2	C,	slope	=	-0.014).		130	 Further	analysis	of	the	A2/NS4b+	CD8	T	cells	within	the	conventional	Naïve	gate	showed	131	 different	behaviors	for	the	Naïvehigh	versus	the	Naïveint	cells.	The	latter	were	sharply	132	
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induced	by	the	vaccine,	reaching	frequencies	up	to	2.46%,	with	a	slow	but	significant	133	 decrease	with	time	(fig.	2	B,	“Naïveint”	panel;	fig.	2	C:	slope	-0.034).	In	contrast,	the	Naïvehigh	134	 A2/NS4b+	CD8	T	cells	barely	increased,	only	by	an	average	1.5-fold	in	vaccinated	versus	135	 detectable	unvaccinated	donors	(note	also	that	most	unvaccinated	donors	(7/10)	had	136	 A2/NS4b+	frequencies	below	the	detection	limit	of	<0.01%).	The	Naïvehigh	A2/NS4b+	CD8	137	 T	cells	also	showed	a	strikingly	flat	time-course	(fig.	2	B,	“Naïvehigh”	panel,	fig.	2	C:	slope	=	-138	 0.00009).		139	 As	an	additional	observation,	the	four	vaccinees	with	a	history	of	multiple	vaccines	(table	140	 S1)	showed	frequencies	and	phenotype	of	A2/NS4b+	CD8	T	comparable	to	single-shot	141	 vaccinees	(fig.	1	B	and	fig.	2).		142	
	143	
	144	
Naïve-like	YF-specific	CD8	T	cells	induced	by	the	YF-17D	vaccine	are	distinct	from	145	
genuine	Naïve	cells	and	resemble	the	stem	cell-like	memory	subset		146	 	147	 We	next	focused	on	the	characterization	of	these	newly	identified	Naïve-like	CD8	T	cells	148	 induced	by	vaccination	with	YF-17D.	It	was	critical	to	evaluate	the	“memory”	nature	of	149	 such	cells	that	fall	in	the	conventional	Naïve	gate.	Recently,	a	new	memory	subset	that	also	150	 co-expresses	CCR7	and	CD45RA	has	been	reported	and	termed	the	stem	cell-like	memory	151	 (Tscm)	subset	(23-25).	Tscm	have	properties	of	differentiated	cells	yet	retain	high	152	 stemness	and	phenotypical	proximity	to	Naïve	cells	–	they	were	also	originally	described	as	153	 “Naïve-like”	before	coining	Tscm.	We	therefore	performed	a	detailed	characterization	of	154	 YF-specific	CD8	T	cells	with	a	two-fold	focus:	i)	to	address	whether	they	are	truly	distinct	155	 from	genuine	Naïve	cells	and	ii)	to	assess	similarities	to	the	recently	reported	Tscm	subset.	156	 	157	
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We	performed	a	thorough	screen	using	a	wide	panel	of	markers	to	study	YF-specific	CD8	T	158	 cells	amongst	the	characteristic	profiles	of	the	differentiation	subsets.	This	panel	included	159	 conventional	and	previously	reported	differentiation	markers	(CD27,	CD28,	CD45RO,	IL-160	 7Rα/CD127,	CD62L,	CCR5,	Granzymes	A	and	B,	Perforin,	BTLA,	PD1,	PDL1,	KLRG1,	2B4	(6,	161	
26),	markers	that	have	been	used	to	distinguish	the	stem	cell-like	memory	subsets	(CD58,	162	 CD95,	CXCR3,	IL-2Rβ/CD122,	CD11a	(alpha	chain	of	LFA-1),	CD161,	IL-18Rα,	ABC-B1	(23,	163	
25,	27,	28),	markers	that	showed	potential	relevance	in	differentiation	and	migration	164	 (CCR4,	CLA	(29),	resident	memory	markers	CD69	and	CD103	(30),	activation	markers	HLA-165	 DR,	CD38	(13,	16))	and	other	related	markers	(IL-2Rα/CD25,	IL-15Rα/CD215,	ICOS).	This	166	 wide	marker	screen	was	performed	on	a	representative	selection	of	16	vaccinees,	spanning	167	 up	to	17	years	after	vaccination	(fig.	S2	A).	As	shown	above,	the	majority	of	A2/NS4b+	cells	168	 were	either	EMRA	or	Naïve-like.	169	 	170	 First,	to	assess	whether	the	Naïve-like	A2/NS4b+	CD8	T	cells	in	vaccinees	were	truly	171	 distinct	from	genuine	Naïve	cells,	A2/NS4b+	CD8	T	cells	in	unvaccinated	individuals	were	172	 studied	in	more	detail.	This	was	technically	challenging	due	to	the	low	frequencies	in	173	 unvaccinated	individuals,	which	were	generally	close	to	the	detection	threshold	of	0.01%	174	 of	Total	CD8	T	cells	(fig.	1	B).	Analysis	was	nevertheless	possible	in	five	unvaccinated	175	 donors	with	sufficient	A2/NS4b+	CD8	T	cells	(>35	cells	detected)	and	showed	that	these	176	 fell	in	the	Naïve	gate	(fig.	3	A	and	B).	Pertinently,	these	also	expressed	CD28	and	CD27	but	177	 did	not	express	markers	characteristic	of	the	Tscm	subset,	notably	CD58,	CD95	and	CXCR3	178	
(6,	23,	25,	27)	(fig.	3C	and	D).	In	contrast,	Naïve-like	A2/NS4b+	CD8	T	cells	from	vaccinees	179	 did	show	positive	expression	for	the	Tscm	markers	CD58,	CD95	and	CXCR3	(fig.	3C	and	D).	180	 Therefore,	the	Naïve-like	A2/NS4b+	CD8	T	cells	in	vaccinees	were	truly	distinct	from	181	 genuinely	Naïve	A2/NS4b+	CD8	T	cells	found	in	unvaccinated	individuals	and	rather	182	
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corresponded	to	the	Tscm	subset.	In	agreement,	the	Total	Tscm	subset	was	analyzed	based	183	 on	gating	the	minor	population	of	cells	expressing	CD58	and	CD95	within	the	Total	Naïve	184	 population	(fig.	3E).	This	showed	a	prominent	population	of	A2/NS4b+	Tscm	cells	in	185	 vaccinees	(average	0.98%	A2/NS4b+	cells	within	Tscm)	as	opposed	to	unvaccinated	186	 individuals,	where	A2/NS4b+	cells	were	not	detectable	within	Tscm	(fig.	3F).		187	 	188	 A	wide	variety	of	markers	were	further	analyzed	in	vaccinees,	comparing	A2/NS4b+	CD8	T	189	 populations	to	the	respective	reference	populations	in	Total	CD8	T	cells.	In	addition	to	190	 CD58,	CD95	and	CXCR3	mentioned	above,	A2/NS4b+	Naïve-like	CD8	T	cells	distinctly	191	 expressed	IL-2Rβ, 	CD11ahigh,	KLRG1,	Granzyme	A,	IL-18Rα	and	CD45RO,	in	clear	contrast	192	 to	the	Total	Naïve	population	(fig.	3	G	and	H).	Interestingly,	the	profile	of	A2/NS4b+	EMRA	193	 cells	was	overall	close	to	the	Total	EMRA	population	but	displayed	particularly	elevated	194	 levels	of	CD28,	CD27,	IL-7Ra,	CXCR3,	CD62L,	BTLA	and	IL-18Rα.	The	latter	is	in	agreement	195	 with	previous	studies	where	YF	vaccination	was	reported	to	raise	a	particular	type	of	196	 EMRA	cells	that	defy	the	terminally	differentiated	phenotype	generally	attributed	to	the	197	 EMRA	subset	(10,	13,	31,	32).	While	the	majority	of	A2/NS4b+	CD8	T	cells	were	Naïve-like	198	 or	EMRA,	there	were	sufficient	events	in	EM	and	CM	gates	of	A2/NS4b+	CD8	T	cells	in	199	 several	donors	for	flow	cytometry	analyses;	the	complete	data	series,	including	the	31	200	 markers	and	all	detectable	subsets	are	detailed	in	fig.	S2	B.	Considering	the	markers	201	 overall,	it	was	only	the	A2/NS4b+	Naïve-like	CD8	T	cells	that	showed	a	significantly	202	 different	profile	as	compared	to	the	corresponding	reference	population	(i.e.	versus	Total	203	 Naïve;	Wilcoxon	comparisons	in	fig.	3	H	and	fig.	S2	B).	204	 	205	 Additionally,	in	order	to	investigate	changes	over	time	since	vaccination,	we	selected	the	206	 eight	markers	that	showed	greatest	differences	between	vaccine-induced	A2/NS4b+	Naïve-207	
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like	CD8	T	cells	and	the	Total	Naïve:	CD58,	CD95,	CXCR3,	KLRG1,	CD11ahigh,	IL-18Ra,	208	 Granzyme	A	and	IL-2Rb.	The	time-span	of	vaccination	in	the	selection	of	16	donors	was	209	 ≈17.5	years.	Considering	the	“years	since	vaccination”	(fig.	S2	C),	the	levels	of	all	markers	210	 within	Naïve-like	A2/NS4b+	CD8	T	cells	had	a	slight	tendency	to	decrease,	statistically	211	 significant	for	IL-2Rb	and	CXCR3.	The	reference	Total	Naïve	cells	also	displayed	a	tendency	212	 for	lower	CXCR3	and	higher	CD58	with	time,	pointing	towards	inter-donor	variation	for	213	 these	two	markers.	Nevertheless,	for	the	eight	markers,	the	A2/NS4b+	Naïve-like	cells	214	 expressed	distinctly	superior	levels	as	compared	to	the	Total	Naïve	population,	even	in	the	215	 second	decade	after	vaccination.	216	 		217	 	218	
Naïve-like	Tscm	are	also	found	in	other	viral	antigen-specificities	219	 	220	 T	cells	with	various	viral	specificities	and	particular	T	cell	differentiation	stages	have	been	221	 thoroughly	studied	in	humans	and	are	frequently	used	as	reference	populations.	These	222	 specificities	pertain	to	relatively	prevalent	chronic	or	acute	viral	infections	such	as	HCV,	223	 Flu,	EBV,	HIV	and	CMV,	which,	in	this	order,	display	increasing	differentiation	status(6).	224	 In	order	to	compare	YF-specific	CD8	T	cells	to	other	antigen	specificities,	we	further	225	 analyzed	the	16	donors	for	CD8	T	cells	specific	for	Flu,	EBV	and	CMV	(fig.	4).	In	addition,	we	226	 studied	Melan-A-specific	CD8	T	cells	as	a	population	of	cells	that	displays	a	truly	naïve	227	 quality	in	healthy	donors	not	bearing	melanoma	nor	diagnosed	with	vitiligo	(31,	32).	All	16	228	 vaccinees	had	detectable	populations	specific	for	Melan-A	and	Flu,	13	were	positive	for	229	 EBV,	and	5	for	CMV	(fig.	4	B).	As	expected,	Melan-A-specific	CD8	T	cells	were	230	 predominantly	Naïve,	while	Flu-,	EBV-	and	CMV-specific	CD8	T	cells	showed	subset	231	 distributions	with	increasing	differentiation	(CM	à	EM	à	EMRA)	(fig.	4	C).	All	specificities	232	
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showed	cells	falling	in	the	conventional	Naïve	gate	(fig.	4	A	and	C).	Further	analysis	of	233	 CD58,	CD95	and	CXCR3	revealed	that,	within	the	Naïve	gate,	Melan-A-specific	cells	were	234	 mostly	CD58-	CD95-	CXCR3low,	supporting	the	notion	that	these	cells	are	genuinely	Naïve.	235	 In	contrast,	all	viral	antigen-specific	cells	showed	Naïve-like	cells	triple	positive	for	CD58,	236	 CD95	and	CXCR3,	albeit	at	varying	degrees.	Flu-specific	Naïve-like	CD8	T	cells	were	more	237	 variable	depending	on	the	donor,	while	EBV-	and	CMV-specific	cells	were	particularly	high	238	 in	CD58	and	CD95	expression.	For	CXCR3,	YF-	and	CMV-specific	CD8	T	cells	showed	higher	239	 expression	(fig.	4	D).	Interestingly,	Flu-specific	Naïve-like	CD8	T	cells	often	showed	a	split	240	 population	for	CD58	and	CD95.	This	may	be	due	to	the	presence	of	both	genuine	Naïve	and	241	 Naïve-like	cells,	presumably	depending	on	the	history	of	Flu	vaccination	and/or	infection.	242	 The	latter	was	however	difficult	to	track	in	our	donors,	given	the	endemic	nature	of	Flu	243	 worldwide.		244	 	245	 Our	data	overall	indicated	that	the	Naïve-like	subset	was	also	detected	in	other	viral	246	 specificities	and	generally	differed	from	the	reference	Naïve	population	in	total	CD8	T	cells	247	 and	from	self	antigen-specific	Naïve	CD8	T	cells.	248	 	249	 In	addition,	we	addressed	whether	Naïve-like	CD8	T	cells	were	also	generated	with	250	 specificities	other	than	the	HLA-A*02-restricted	NS4b214-222	(LLWNGPMAV).	Previous	251	 studies	using	stimulation	of	YF	vaccinee	samples	with	peptide	pools	have	shown	that	the	252	 CD8	T	cell	response	can	be	diverse	and	highly	variable	across	donors,	yet	HLA-A*02	253	 positive	donors	consistently	display	responses	to	NS4b214-222	(13,	14,	16).	In	fact,	only	a	254	 limited	number	of	epitopes	other	than	A2/NS4b,	or	peptide	pools	activating	vaccinee	255	 samples,	have	been	described	(13,	14,	16,	20).	Based	on	these	studies	and	HLA-binding	256	 predictions	(BIMAS	and	SYFPEITHI),	we	generated	a	selection	of	nonamer	or	decamer	257	
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epitopes	alternative	to	the	A2/NS4b	that	could	potentially	yield	tetramer	stainings	in	YF	258	 vaccinees.	Following	the	HLA-typing	information	available	in	our	cohort,	we	could	test	non-259	 HLA-A*02	restricted	epitopes:	“B35/HPF”	in	three	vaccinees,	“B7/RPI”	in	four	vaccinees	260	 and	“A24/VYM”	in	one	vaccinee;	plus	HLA-A*02	restricted	epitopes	in	25	vaccinees:	261	 “A2/AMD”,	“A2/VML”,	“A2/VCY”	and	“A2/GIL”	(fig.	S3).	Of	note,	many	vaccinees	in	our	262	 cohort	did	not	have	the	appropriate	HLA	type	to	analyze	the	aforementioned	selection	of	263	 Yellow	Fever	epitopes.	Out	of	108	samples	tested,	this	screen	resulted	in	4	positive	samples	264	 (tetramer	positive	cells	>	0.01%	in	total	CD8	T	cells),	including	two	for	“A2/VML”	and	two	265	 for	“B7/RPI”	(fig.	S3	A).	Analyses	of	these	tetramer	positive	cells	subsequently	showed	that	266	 B7/RPI+	CD8	T	cells	could	also	display	a	Naïve-like	Tscm	phenotype	(falling	in	the	267	 conventional	Naïve	gate	yet	expressing	CD58	and	CD95)	(fig.	S3	B).		Donor	LAU	5005	had	268	 particularly	high	frequencies	of	Naïve-like	B7/RPI+	CD8	T	cells	(90%)	while	the	two	269	 A2/VML	positive	samples	showed	very	few	Naïve-like	cells	(0.5	–	2.8	%)	(fig.	S3	B).	270	 Nonetheless,	the	screen	showed	that	Naïve-like	Tscm	subsets	were	also	generated	against	271	 epitopes	other	than	A2/NS4b,	in	particular	the	B7/RPI.	Together	with	the	evidence	on	272	 Naïve-like	CD8	T	cells	found	in	other	viral	specificities	(fig.	4),	this	shows	that	generation	of	273	 Naïve-like	Tscm	is	not	exclusive	to	A2/NS4b+	CD8	T	cells.		274	 	275	 	276	
Naïve-like	YF-specific	CD8	T	cells	display	mRNA	profiles	that	are	close	to	Tscm	cells	277	
and	with	high	preservation	of	“Naïveness”	278	 	279	 In	order	to	comprehend	the	global	particularities	of	YF	vaccine-induced	Naïve-like	CD8	T	280	 cells,	we	analyzed	their	genome-wide	mRNA	profile	and	compared	it	to	the	conventional	281	 subsets	in	total	CD8	T	cells.	The	latter	included	Naïve,	CM	and	a	pool	of	EM	and	EMRA	282	
		 14	
referred	to	as	“Effectors”.	We	also	analyzed	the	Tscm	subset	(23,	25),	gated	as	the	minor	283	 population	expressing	CD58	and	CD95	within	the	Naïve	gate	of	total	CD8	T	cells.	These	five	284	 populations	were	isolated	from	each	of	eight	selected	vaccinees,	spanning	over	17	years	of	285	 vaccination	history.	The	sorting	strategy	and	the	subset	distribution	of	cells	from	vaccinees	286	 are	shown	in	fig.	S4.	287	 	288	 Most	remarkably,	principal	component	analysis	clearly	showed	a	gradient	of	differentiation	289	 along	the	first	principal	component	(PC1),	from	Naïve	to	a	mixture	of	Tscm/CM	to	effectors.	290	 Within	this	gradient,	the	A2/NS4b+	Naïve-like	CD8	T	cells	clustered	near	the	Tscm/CM	291	 samples	(fig.	5	A	to	C).	Moreover,	amongst	all	differentiated	populations,	A2/NS4b+	Naïve-292	 like	CD8	T	cells	lied	distinctly	closest	to	the	Naïve	subset	(fig.	5	A	to	C).	These	observations	293	 were	further	confirmed	quantitatively	based	on	pairwise	comparisons	to	calculate	inter-294	 sample	distances	along	PC1.	The	Naïve-like	A2/NS4b+	CD8	T	cells	were	most	closely	295	 related	to	the	Tscm	subset	(fig.	5	D,	left	panel:	“comparisons	to	A2/NS4b+	Naïve-like”).	In	296	 addition,	the	Naïve-like	A2/NS4b+	CD8	T	cells	were	closest	in	the	comparison	to	the	297	 reference	Naïve	subset	(fig.	5	D,	right	panel:	“comparisons	to	Total	Naïve”).	The	Total	Tscm	298	 samples	were	generally	found	interspersed	with	the	Total	CM	samples	(fig.	5	B	and	C).	299	 Pertinently,	by	considering	the	genesets	that	define	“Differentiation”	in	CD8	T	subsets	as	300	 well	as	the	differences	in	“Tscm	vs.	Naïve”	as	described	in	the	report	of	the	Tscm	subset	301	
(23),	we	could	similarly	observe	that	the	A2/NS4b+	Naïve-like	CD8	T	cells	were	closely	302	 clustered	together	and	displayed	a	profile	between	the	CM/Tscm	and	Naïve	cells	(fig.	S4	E	303	 and	F).	304	 	305	 Very	few	genes	were	significantly	differentially	expressed	between	the	A2/NS4b+	Naïve-306	 like	CD8	T	cells	and	the	Total	Naïve,	Total	Tscm	or	Total	CM,	due	to	inter-sample	variation	307	
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in	the	context	of	relatively	small	mRNA	differences,	and	in	contrast	to	the	numerous	308	 significant	genes	in	the	comparison	to	the	Total	Effectors	(table	S3).	The	analysis	of	mRNA	309	 profiles	altogether	showed	that	contributions	from	large	numbers	of	genes	globally	310	 differentiated	the	various	subsets.	These	global	differences	reflected	a	gradient	of	311	 differentiation	that	suggests	that	the	A2/NS4b+	Naïve-like	CD8	T	cells,	amongst	all	312	 differentiated	subsets,	have	globally	preserved	most	“Naïveness”.		313	 	314	 	315	 	316	
Long-term	persisting	YF-specific	CD8	T	cells	respond	to	cognate	peptide	and	show	317	
homeostatic	proliferation	with	IL-15,	with	a	proliferative	advantage	for	the	Naïve-318	
like	phenotype	319	 	320	 As	compared	to	Naïve	cells	that	have	never	been	primed,	memory	CD8	T	cells	readily	321	 respond	to	cognate	antigen	and	are	capable	of	homeostatic	proliferation	in	presence	of	IL-322	 15	(23,	33).	Therefore,	we	assessed	the	proliferation	capacity	of	YF-specific	CD8	T	cells,	and	323	 its	link	to	the	Naïve-like	phenotype.	Due	to	the	limited	bioavailability	of	samples	(technical	324	 limitation	detailed	in	discussion),	we	could	not	analyze	individually	isolated	subsets	of	325	 A2/NS4b+	CD8	T	cells	from	large	numbers	of	donors	and	stimulate	with	multiple	326	 conditions.	We	therefore	first	stimulated	PBMC	from	vaccinees	with	the	NS4b	peptide	in	327	 the	presence	of	IL-2	or	IL-15	or	treated	with	either	cytokine	alone.	PBMC	from	three	328	 unvaccinated	individuals	served	as	controls.	Both	in	the	presence	of	IL-2	or	IL-15,	329	 A2/NS4b+	CD8	T	cells	from	the	large	majority	of	vaccinees	proliferated	efficiently	in	330	 response	to	cognate	NS4b	peptide	(fig.	6A).	Importantly,	while	IL-2	alone	generally	331	 resulted	in	no	expansion,	IL-15	alone	induced	considerable	expansion,	demonstrating	IL-332	
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15-driven	homeostatic	proliferation	characteristic	of	memory	cells	(fig.	6	A).		Pertinently,	333	 the	A2/NS4b+	CD8	T	cells	from	the	three	unvaccinated	individuals	did	not	show	334	 proliferation,	in	agreement	with	their	genuine	Naïve	status	(fig.	6A).		335	 		336	 In	order	to	assess	the	link	between	the	Naïve-like	phenotype	and	proliferation	capacity,	the	337	 expansion	was	compared	to	the	starting	frequency	of	Naïve-like	cells	(fig.	6	B).	In	spite	of	338	 the	variability	amongst	samples,	a	higher	starting	frequency	of	Naïve-like	cells	significantly	339	 correlated	with	greater	expansion	in	response	to	peptide	and	IL-15,	and	a	tendency	in	this	340	 direction	was	seen	with	peptide	and	IL-2	(p	=	0.068).	Interestingly,	a	higher	starting	Naïve-341	 like	frequency	was	also	significantly	associated	with	greater	homeostatic	proliferation	with	342	 IL-15	alone	and	with	better	survival	with	IL-2	alone	(fig.	6	B).	In	addition,	the	capacity	to	343	 respond	to	peptide	was	relatively	stable	long-term	after	vaccination,	over	15	years	after	344	 vaccination	(fig.	S5	A).	345	 	346	 	347	
Naïve-like	YF-specific	CD8	T	cells	expanded	in	vitro	generate	effectors	and	show	self-348	
renewal	349	
	350	 The	defining	property	of	stem	cells	is	their	capacity	to	self-renew	(34,	35).	A	fundamental	351	 question	was	therefore	to	assess	the	quality	of	the	progeny	of	Naïve-like	A2/NS4b+	CD8	T	352	 cells.	To	this	end,	Naïve-like	A2/NS4b+	CD8	T	cells	were	purified	and	expanded	in	vitro,	in	353	 comparison	to	Non-Naïve	counterparts.	Since	we	started	with	very	low	numbers	of	cells,	354	 we	stimulated	with	PHA,	IL-2	and	irradiated	feeders,	a	protocol	that	is	used	for	T	cells	355	 cloning	because	it	provides	robust	polyclonal	stimulation.	By	day	14,	sufficient	cells	were	356	 yielded	to	analyze	the	progeny	generated	from	either	Naïve-like	(n=5)	or	Non-Naïve	(n=4)	357	 A2/NS4b+	CD8	T	cells.	Both	progenies	displayed	CCR7-	effectors	(fig.	6	C).	The	Non-Naïve	358	
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progeny	showed	a	slightly	increased	population	doubling	and	higher	proportion	of	EM	as	359	 opposed	to	EMRA	in	the	progeny	of	Naïve-like	(fig.	S5	B	to	D).	The	effector	progeny	from	360	 Naïve-like	showed	loss	of	Naïve	markers	CD28,	CD27	and	IL-7Rα,	demonstrating	typical	361	 differentiation	and	not	merely	loss	of	CCR7	(fig.	S5	B	and	E).	Critically,	the	purified	Naïve-362	 like	A2/NS4b+	CD8	T	cells,	and	not	the	purified	Non-Naïve,	generated	a	small	fraction	of	363	 expanded	cells	that	retained	the	Naïve-like	phenotype	(fig.	6	C	and	D).	This	was	not	due	to	364	 the	lack	of	stimulation	of	a	fraction	of	starting	Naïve-like	cells	because	the	numbers	of	365	 Naïve-like	cells	were	slightly	yet	effectively	increased	as	compared	to	the	input	(fig.	6	E).	366	 Therefore,	the	Naïve-like	A2/NS4b+	CD8	T	cells	demonstrated	self-renewal,	in	support	of	367	 their	stemness	potential.	368	
	369	 In	addition,	we	assessed	Naïve-like	or	Non-Naïve	A2/NS4b+	CD8	T	cells	for	short-term	370	 functional	readouts,	in	comparison	to	the	reference	subsets	in	Total	CD8	T	cells,	using	371	 polyclonal	anti-CD3	and	anti-CD28	stimulation.	First,	we	analyzed	the	proliferative	marker	372	 Ki67	and	the	activation	marker	HLA-DR	as	early	as	possible	i.e.	at	24h,	in	order	to	avoid	373	 substantial	changes	in	subset	composition,	as	it	naturally	occurs	within	the	first	days	of	T	374	 cell	activation	(26).	As	previously	shown	using	isolated	subsets	from	non-human	primates	375	
(24),	the	Total	Tscm	subset	showed	highest	Ki67	expression	amongst	all	subsets,	and	only	376	 Naïve	cells	did	not	upregulate	HLA-DR	(fig.	6	F	and	S5	F).	Intriguingly,	within	A2/NS4b+	377	 CD8	T	cells,	the	Naïve-like	population	behaved	similarly	to	the	reference	Total	Naïve,	while	378	 Non-Naïve	A2/NS4b+	cells	were	comparable	to	Total	EM	and	EMRA	subsets.	(fig.	6	F).	379	 Secretion	of	IFNγ,	TNFα	and	IL-2	was	also	assessed	at	4h	after	anti-CD3	and	anti-CD28	380	 stimulation.	However,	the	medium	control	showed	substantial	background	secretion	in	381	 A2/NS4b+	populations,	which	could	be	due	to	activation	by	the	tetramer	staining	382	 (unavoidable	for	the	experiment).	This	technical	limitation	precluded	conclusions	when	383	
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comparing	A2/NS4b+	to	the	reference	subsets	in	total	CD8	T	cells	(not	stained	with	384	 tetramer)	(fig.	S6).		385	 	386	 Overall,	these	short-term	functional	assays	showed	that	the	behavior	of	Naïve-like	387	 A2/NS4b+	CD8	T	cells	was	close	to	the	reference	Total	Naïve	subset,	in	agreement	with	388	 their	high	degree	of	“Naïveness”	observed	in	the	whole	transcriptome	analyses	described	389	 in	fig.	5.	 	390	
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Discussion	391	 	392	 	393	 In	this	study,	we	report	two	major	findings	that	provide	new	insights	into	the	biology	of	394	 long-term	persisting	human	memory	CD8	T	cells.	First,	the	YF-17D	vaccine	induced	a	395	 population	of	Naïve-like	memory	CD8	T	cells	that	resembles	the	recently	described	Tscm	396	 subset	and	preserves	a	high	degree	of	“Naïveness”.	This	was	detected	in	a	controlled	397	 setting,	that	is,	in	an	antigen-specific	setting	with	a	known	time	of	antigen	priming	in	398	 humans.		Second,	the	A2/NS4b+	Naïve-like	population	appeared	stable	over	at	least	25	399	 years	of	vaccination	history.	This	setting	provided	proof	for	the	longevity	and	stability	of	400	 CD8	Tscm	in	humans,	being	in	the	range	of	decades.	401	 	402	 Several	studies	have	previously	analyzed	the	frequencies	and	differentiation	status	of	YF	403	 vaccine-induced	CD8	T	cells	early	following	vaccination.	These	include	consideration	of	404	 several	epitopes	up	to	90	days	post-vaccination	(16),	analyses	on	various	differentiation	405	 markers	mostly	within	the	first	90	days	and	with	limited	numbers	of	donors	up	to	27	406	 months	(13)	as	well	as	describing	the	TCR	repertoire	in	two	donors	up	to	54	months	post-407	 vaccination	(20).	Overall,	these	studies	found	a	predominant	EMRA	population	that	is	408	 highly	polyfunctional,	which	is	unexpected	for	EMRA	cells	as	they	are	normally	considered	409	 to	be	terminally	differentiated	(10).	Of	note,	similar	observations	were	made	in	CD8	T	cells	410	 induced	by	the	Smallpox	vaccine,	a	second	live-attenuated	vaccine	that	triggers	very	411	 effective	CD8	T	cells	in	humans	(10,	15).		412	 Relevant	to	our	findings,	the	flow	cytometry	data	presented	in	these	previous	reports	also	413	 shows	evidence	for	a	CD45RA+	CCR7+	double	positive	population	in	YF-specific	CD8	T	414	 cells,	either	within	the	first	90	days	(n=up	to	15)	(13,	16)	or	in	limited	numbers	of	donors	415	
		 20	
up	to	46	months	(n=	1	to	3)	post-vaccination	(13,	20).	This	would	correspond	to	the	Naïve-416	 like	A2/NS4b+	CD8	T	cells	that	we	hereby	report.	However,	this	detection	of	Naïve-like	417	 memory	CD8	T	cells	was	neglected	amidst	the	focus	on	the	effector	populations	raised	by	418	 the	vaccine.	Our	study	analyzed	A2/NS4b+	CD8	T	cells	both	beyond	5	years	after	419	 vaccination	and	in	a	considerably	large	cohort	(n	>20).	We	thoroughly	characterized	this	420	 Naïve-like	subset	raised	by	the	YF	vaccine,	and	discovered	that	it	resembles	Tscm	and	421	 becomes	particularly	predominant	in	the	long-term	(range	of	decades).		422	 	423	 The	phenotypic	observation	that	A2/NS4b+	CD8	T	cells	from	vaccinees	falling	in	the	424	 conventional	Naïve	gate	can	express	varying	levels	of	CD45RA	and	CCR7	remains	425	 intriguing.	Interestingly,	the	A2/NS4b+	Naïvehigh	population	only	increased	by	1.5-fold	in	426	 frequency	between	detectable	unvaccinated	controls	and	vaccinees.	Yet,	there	was	a	clear	427	 change	in	phenotype,	from	genuine	Naïve	(CD58-	CD95-)	in	unvaccinated	controls	to	Tscm	428	 (CD58+	CD95+)	in	vaccinees.	This	particular	phenotypic	shift	and	the	threshold	of	tetramer	429	 staining	used	(0.01%	and	>20	events,	i.e.	considerably	high)	supports	that	the	cells	430	 analyzed	were	not	merely	background.	Background	events	would	have	shown	a	431	 distribution	of	subsets	close	to	the	total	population	of	cells.	Regarding	the	various	432	 populations	characterized,	our	study	is	primarily	descriptive	of	the	phenotypic	433	 observations	that	can	be	made	in	the	study	of	YF-specific	CD8	T	cells	in	vaccinees,	and	in	434	 relation	to	the	memory	subsets	that	have	been	described.	In	table	1,	we	summarize	the	435	 populations	that	are	referred	to	in	this	study,	including	conventional	subsets	in	total	CD8	T	436	 cells,	the	recently	reported	Tscm	subset,	and	the	A2/NS4b+	populations	that	we	437	 characterized	in	unvacccinated	individuals	and	vaccinees.	The	fact	that	Tscm	populations	438	 (whether	the	reference	Total	Tscm,	or	the	Naïve-like	A2/NS4b+	CD8	T	cells)	are	found	439	
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within	the	conventional	Naïve	gate	raises	concerns	on	our	current	definition	of	memory	440	 subsets	and	Naïve	cells,	popularly	defined	by	CCR7	and	CD45RA	(6).	441	
	442	 Out	of	all	memory	subsets,	Tscm	are	thought	to	have	retained	the	most	“stemness”,	to	be	443	 closest	to	the	Naïve	cells,	and	thus	represent	a	subset	of	utmost	interest	for	long-term	444	 immunity	(4,	24,	36).	In	the	framework	of	adoptive	T	cell	therapy,	the	least	differentiated	445	 memory	cells	are	thought	to	be	the	best	source	to	generate	a	progeny	of	potent	anti-tumor	446	 CD8	T	cells	and	self-renew	for	long-term	therapeutic	efficacy	(4,	24,	37-39).	Recently,	serial	447	 adoptive	transfers	of	single	CD62L+	CM	cells	in	mice	demonstrated	better	stemness	as	448	 opposed	to	more	differentiated	EM	cells,	by	reconstituting	immunocompetence	against	449	 infection	with	listeria	monocytogenes	(40).	In	humans	and	non-human	primates,	the	450	 quantity	and	quality	of	the	progeny	of	the	various	subsets	has	been	assessed	by	451	 proliferation	assays	in	vitro.	It	has	been	found	that	in	particular	Naïve	cells	and	Tscm	can	452	 self-renew	and	reconstitute	the	other	differentiated	populations	(including	Tscm	when	453	 starting	with	Naïve)	(23,	24).	In	fact,	Naïve	cells	represent	the	mature	T	cell	type	that	is	454	 ready	to	encounter	antigen	with	the	highest	stemness	and	pluripotency,	potentially	455	 producing	all	types	of	effector	and	memory	progenies	(36,	37,	41).	Yet	Naïve	cells	remain	to	456	 be	optimally	primed	to	respond	to	their	cognate	antigen,	and	adoptive	T	cell	transfers	rely	457	 on	the	isolation	and	amplification	of	T	cells,	which	inevitably	induces	differentiation.	There	458	 is	thus	a	quest	to	optimally	prime	and	minimally	differentiate	T	cells,	to	generate	memory	459	 cells	that	preserve	highest	proximity	to	Naïve	and	thus	immunotherapeutic	potential.		460	 Intriguingly,	from	our	genome-wide	mRNA	profiling	data,	there	is	no	apparent	set	of	genes	461	 or	a	signature	that	minimally	and	significantly	defines	the	A2/NS4b+	Naïve-like	CD8	T	cells.	462	 In	fact,	very	few	genes	were	significantly	differentially	expressed	between	Naïve,	CM,	Tscm	463	 or	the	A2/NA4b+	Naïve-like	CD8	T	cells.	Rather,	the	analyses	across	samples	highlighted	a	464	
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differentiation	gradient	defined	globally	by	contributions	from	several	genes,	transitioning	465	 from	Naïve	to	A2/SN4b+	Naïve-like	to	a	mixture	of	Tscm/CM	to	Effectors.	This	supports	the	466	 notion	that	CD8	T	cells	undergo	differentiation	programs	upon	priming,	within	which	467	 memory	cells	may	retain	varying	proximity	to	the	Naïve	cells.	In	the	course	of	an	immune	468	 response,	memory	precursors	that	are	rescued	at	the	earliest	differentiation	stage	would	469	 generate	memory	populations	that	preserve	higher	stemness	and	multipotency	(36,	42).	470	 Thus,	the	proximity	to	the	Naïve	cells,	that	is,	the	“Naïveness”	of	a	memory	cell	may	be	471	 regarded	as	the	parameter	that	reflects	early	rescue	and	may	therefore	serve	as	a	measure	472	 of	memory	quality.	In	this	regard,	“Naïveness”	is	beyond	the	property	of	stemness	and	473	 reflects	globally	the	preservation	of	Naïve	properties.	Overall,	we	found	that	Naïve-like	474	 A2/NS4b+	CD8	T	cells:	i)	phenotypically	resembled	the	Tscm	subset	by	expressing	markers	475	 such	as	CD58,	CD95,	CXCR3,	IL-2Rβ and	high	LFA-1	(23),	ii)	efficiently	responded	to	476	 cognate	peptide	and	IL-15-driven	homeostatic	proliferation,	in	contrast	to	genuine	Naïve	477	 cells;	and	iii)	showed	self-renewal	capacity.	Yet	A2/NS4b+	Naïve-like	CD8	T	were	not	478	 identical	to	the	reference	Total	Tscm	and	also	shared	certain	behaviors	with	the	reference	479	 Naïve	subset,	as	observed	in	the	genome-wide	transcriptome	profile	and	short-term	480	 functional	characteristics	(early	Ki67	and	HLA-DR	upregulation	upon	activation).	In	fact,	in	481	 the	latter	analyses,	the	Total	Tscm	were	very	close	to	Total	CM.	Altogether,	it	is	possible	482	 that	there	is	substantial	variation	in	the	quality	of	various	antigen-specific	Tscm	cells	(and	483	 memory	subsets	in	general),	with	different	histories	of	priming	and	antigen	exposure	that	484	 may	impact	on	phenotype	and	functionality.	The	high	degree	of	“Naïveness”	of	YF-specific	485	 CD8	T	cells	may	reflect	absence	of	chronic	or	recent	antigen	exposure,	as	opposed	to	the	486	 Total	Tscm	subset	that	may	contain	variably	and	possibly	relatively	recently	activated	cells.	487	 This	high	“Naïveness”	also	suggests	that	Naïve-like	A2/NS4b+	CD8	T	cells	are	a	particularly	488	 high	quality	population	within	the	Tscm	subset.		489	
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	490	 As	addressed	in	the	results	section,	the	Tscm	subset	described	by	Gattinoni	et	al.	has	also	491	 been	detected	in	the	context	of	cancer	or	viral	specificities,	namely	Melan-A,	CMV	and	Flu	492	
(23).	We	also	detected	Naïve-like	CD8	T	cells	in	CMV-,	EBV-	and	Flu-specific	CD8	T	cells	493	 albeit	with	variation	in	the	expression	of	Tscm	markers	such	as	CD58,	CXCR3	and	CD95.	Yet	494	 the	key	point	in	our	study	is	that	the	exposure	to	Flu,	CMV	and	EBV	viruses	is	difficult	to	495	 track	and	supervise	experimentally,	given	the	chronic	and/or	prevalent	quality	of	these	496	 viral	infections	in	the	human	population.	This	contrasts	to	the	vaccination	setting,	such	as	497	 with	YF-17D,	where	the	parameter	‘time	since	antigen	priming’	is	known.	The	latter	is	the	498	 central	feature	to	demonstrate	the	longevity	of	the	vaccine-induced	Naïve-like	memory	499	 subset	that	we	hereby	report.		500	 Only	a	few	studies	so	far	have	provided	proof	for	persistence	of	CD8	T	cells	of	known	501	 antigen-specificity	in	the	long-term,	in	the	range	of	years	to	decades.	For	instance,	these	502	 concern	detection	of	CD8	and	CD4	T	cell	responses	to	Poliomavirus	in	vaccinated	503	 individuals	over	two	decades	(43)	and	the	detection	of	Measles-specific	CD8	T	cells	up	to	504	 34	years	after	vaccination	(44),	but	no	phenotypic	characterization	was	performed.	A	very	505	 recently	published	study	has	gathered	evidence	that	Tscm	cells	may	survive	at	least	12	506	 years	in	humans,	based	on	the	follow-up	of	T	cell	clones	in	cohorts	of	patients	treated	507	 against	inherited	adenosine	deaminase	immunodeficiency	with	genetically	corrected-508	 hematopoietic	stem	cells	or	peripheral	blood	leukocytes	(45).	Within	our	cohort	of	509	 vaccinees,	the	A2/NS4b+	Naïve-like	CD8	T	cells	were	detectable	for	at	least	25	years.	The	510	 in-depth	analyses	showed	that	A2/NS4b+	Naïve-like	CD8	T	cells	maintained	higher	levels	511	 of	the	eight	markers	(CD58,	CD95,	CXCR3,	KLRG1,	CD11ahigh,	IL-18Rα,	Granzyme	A,	IL-2Rβ)	512	 that	prominently	distinguished	them	from	Total	Naïve,	over	the	17	years	after	vaccination	513	 studied.	Moreover,	we	did	not	observe	a	particular	correlation	between	expansion	in	vitro	514	
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and	the	vaccination	history.	These	points	altogether	suggest	that	the	qualities	of	the	Naïve-515	 like	A2/NS4b+	CD8	T	cells	become	apparent	early	after	vaccination	(the	minimum	516	 vaccination	history	studied	was	0.27	years)	and	remain	relatively	stable	over	the	years-to-517	 decades	after	vaccination.		518	 	519	 Our	study	was	confronted	with	two	major	limitations.	First,	the	study	of	antigen-specific	520	 CD8	T	cells	is	technically	difficult	due	to	their	low	frequencies	in	blood,	which	impose	the	521	 requirement	of	large	quantities	of	cells	per	analysis.	For	instance,	isolation	of	1’000	Naïve-522	 like	A2/NS4b+	CD8	T	cells	(e.g.	samples	for	microarrays)	required	100	to	500	x	10e6	523	 PBMC,	depending	on	the	donor.	A	standard	blood	donation	yields	400-1000	x10e6	PBMC,	524	 and	a	leukapheresis-based	donation	(one	cycle)	yields	2’000	to	8’000	x	10e6	PBMC.	For	an	525	 experiment	using	e.g.	4	samples	of	1’000	purified	A2/NS4b+	CD8	T	cells,	this	would	easily	526	 require	the	use	and	processing	of	a	full	blood	donation.		527	 A	second	limitation	was	the	fact	that	the	study	is	not	longitudinal,	and	we	need	to	consider	528	 the	confounding	variable	of	inter-donor	variability.	Only	longitudinal	studies	may	529	 comprehend	the	development	and	stability	of	this	A2/NS4b+	CD8	Tscm	population	during	530	 YF	vaccination,	including	the	clonotypic	composition,	expansion	and	inter-relations	531	 amongst	subsets,	and	the	reaction	upon	administration	of	a	recall	vaccine.	The	diversity	of	532	 YF	epitopes	across	vaccinees	and	the	high	prevalence	A2/NS4b+	CD8	T	cells	in	HLA-A*02	533	 positive	donors	(fig.	S3,	(13,	14))	raise	questions	on	the	immunodominance	of	YF	epitopes,	534	 whether	host-related	characteristics	(e.g.	HLA	allele)	influence	the	outcome	of	the	immune	535	 response	and	long-term	memory	elicited	by	the	YF	vaccine;	and	whether	there	are	links	to	536	 side-effects	or	the	efficacy	of	protection	to	infection.	In	view	of	the	results	of	our	screen	on	537	 CD8	T	cell	YF	specificities	other	than	A2/NS4b,	very	large	number	of	donors	(beyond	the	538	 size	of	our	cohort)	would	be	necessary	to	accumulate	positive	samples	for	the	various	HLA	539	
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restrictions	and	epitopes.	In	agreement	with	previous	studies	(13,	14),	our	tetramer	screen	540	 illustrated	the	high	prevalence	of	the	A2/NS4b	specificity	(LLWNGPMAV)	and	thus	its	541	 practicality	as	a	model	antigen	in	humans.	Nonetheless,	our	study	has	the	practical	542	 advantage	of	avoiding	the	awaiting	of	decades	to	study	cohorts	of	vaccinees	with	very	long	543	 vaccination	times.	Altogether,	our	results	support	that	YF	vaccination	is	particularly	544	 suitable	to	investigate	innate	and	specific	immune	mechanisms	responsible	for	the	545	 generation	and	maintenance	of	self-renewing	and	very	long-lasting	memory	cells	in	546	 humans.	547	 	 	548	
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Materials	and	Methods	549	
	550	
	551	
Study	design,	population	and	ethics	statement	552	 The	study	was	open	to	healthy	volunteers	aged	18	to	65	years	having	received	the	Yellow	553	 Fever	17D	vaccine	(Stamaril®,	Sanofi	Pasteur	Pty	Ltd)	with	no	limit	on	minimum	or	554	 maximum	vaccination	history.	Vaccinees	were	grouped	according	to	years	since	555	 vaccination:	<1	year	(I),	1-5	years	(II),	5-10	years	(III)	and	>10	years	(IV).	The	targeted	556	 sample	size	was	n=10	per	group,	and	this	was	met	for	all	groups	except	group	I.	No	outliers	557	 were	excluded	from	analyses.	The	study	protocol	was	approved	by	the	Human	Research	558	 Ethics	Committee	of	the	Canton	de	Vaud	(protocol	329/12),	with	healthy	volunteers	559	 participating	under	written	informed	consent.	Eligible	volunteers	donated	blood	according	560	 to	the	standards	of	the	Blood	Transfusion	Center	in	Epalinges,	Switzerland	(Service	561	 Vaudois	de	Transfusion	Sanguine),	and	the	leukocyte-rich	fraction	(buffy	coat)	was	562	 recovered	for	the	study.	For	further	in-depth	analyses	requiring	larger	number	of	cells,	563	 some	of	the	volunteers	(amongst	those	aged	up	to	50	years)	were	also	invited	for	a	564	 leukapheresis-based	donation.	Samples	from	unvaccinated	blood	donors	were	also	565	 obtained	from	the	Blood	Transfusion	Center	in	Epalinges.	566	 		567	
	568	
Peripheral	blood	collection	and	preparation.		569	
	570	 Peripheral	blood	mononuclear	cells	(PBMC)	were	obtained	from	leukocyte-rich	blood	571	 samples	following	density	gradient	fractionation	using	LymphoprepTM.	All	samples	were	572	 immediately	cryopreserved	in	RPMI	1640	supplemented	with	40%	FCS	and	10%	DMSO	573	
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awaiting	experimental	use.		574	 	575	
	576	
Flow	cytometry.		577	 	578	 The	tetramers	and	antibodies	used	are	detailed	in	Table	S4.	For	the	analysis	of	antigen-579	 specific	populations,	CD8	T	cells	were	first	enriched	from	cryopreserved	samples	using	the	580	 human	CD8	T	cell	enrichment	kit	from	StemCellTM	Technologies	(negative	selection,	per	581	 manufacturer’s	instructions).	Stainings	were	performed	using	PBS	with	5mM	EDTA,	0.2%	582	 BSA	and	0.2%	Na-azide	(FACS	buffer).	Tetramer	stainings	were	performed	for	40	min	at	583	 RT.	Surface	antibody	staining	was	then	performed,	followed	by	staining	with	the	fixable	584	 dead-cell	marker	Vivid-Aqua	(Molecular	Probes®,	Invitrogen),	each	step	at	4°C	for	30	min.	585	 Cells	were	fixed	overnight	in	1%	formaldehyde	(supplemented	with	2%	glucose	and	5mM	586	 Na-azide).	Intracellular	staining	was	performed	last,	using	antibodies	in	FACS	buffer	with	587	 0.1%	saponin	for	30	min	at	4°C.	For	Ki-67	intracellular	/	nuclear	staining,	the	fixation	and	588	 permeabilization	was	performed	using	the	reagents	from	the	Foxp3	staining	kit	from	589	 eBioscience.	Samples	were	acquired	using	a	Gallios	flow	cytometer	(Beckman	Coulter,	3-590	 laser	configuration),	with	antibody	panels	limited	to	10-colors.	The	data	was	processed	591	 with	FlowJo	(Tree	Star	Inc.,	v9.5.2).	Samples	with	antigen-specific	populations	below	592	 0.01%	tetramer	positive	cells	in	Total	CD8	T	cells	were	considered	negative.	Populations	593	 consisting	of	less	than	20	events	were	not	considered	eligible	for	further	analysis	(e.g.	no	594	 analysis	of	markers	on	non-naïve	populations	of	A2/NS4b+	CD8	T	cells	in	unvaccinated	595	 individuals).	Isolation	of	cells	for	microarray	analyses	(described	further	below)	was	596	 performed	using	the	a	BD	FACSAria	I	flow	cytometer.		597	 	598	
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Whole	transcriptome	microarrays:	mRNA	sample	preparation	and	analysis	599	 	600	 CD8	T	cells	were	enriched	from	cryopreserved	PBMC	using	the	negative	enrichment	kit	601	 from	StemCellTM.	For	the	flow	cytometry-based	purification,	samples	were	stained	with	602	 A2/NS4b-PE	tetramer	for	40	min,	followed	by	surface	staining	for	30	min	(CD8,	CD45RA,	603	 CCR7,	CD16,	CD58,	CD95;	referenced	above)	and	live/dead	staining	for	30	min.	For	mRNA	604	 analysis	on	whole	transcriptome,	1’000	cells	were	isolated	from	each	of	the	five	different	605	 populations	using	the	strategy	shown	in	fig.	S6,	per	donor	(n=8	donors,	D1	to	D8	ordered	606	 with	increasing	vaccination	history),	by	flow	cytometry-based	purification	directly	into	607	 13.5	ul	of	SumperAmpTM	lysis	buffer	(Miltenyi	Biotec).	From	CD8	T	enrichment,	all	608	 manipulations	including	cell	sorting	were	carried	at	4oC.	After	sorting,	RNA	lysates	were	609	 incubated	for	10	min	at	45oC	and	immediately	frozen	at	-20oC.	Purifications	were	610	 performed	on	two	separate	days	(Sort	I:	D1,	D3,	D4	&	D6;	Sort	II:	D2,	D5,	D7	and	D7).			611	 Thereafter,	frozen	RNA	samples	were	shipped,	processed	and	analyzed	together	by	the	612	 Genomic	Services	of	Miltenyi	Biotec	according	to	their	SuperAmpTM	technology,	and	by	613	 hybridization	onto	Agilent	Whole	Human	Genome	Microarray	8x60K	(V2,	one	color:	Cy3).	614	 The	integrity	of	cDNA	was	checked	via	the	Agilent	2100	Bioanalyzer.	Fluorescence	signals	615	 of	the	hybridized	Agilent	Microarrays	were	detected	using	Agilent’s	Microarray	Scanner	616	 System	(Agilent	Technologies).	Raw	output	data	were	generated	via	the	Agilent	Feature	617	 Extraction	software.	The	raw	data	was	background	corrected	and	quantile	normalized	618	 using	the	backgroundCorrect	and	normalizeBetweenArrays	functions	in	the	limma	R	619	 package	(version	3.20.8,	R	version	3.1.0).	Control	probes	and	probes	whose	normalized	620	 expression	value	did	not	exceed	the	background	level	in	any	of	the	samples	were	filtered	621	 out,	and	the	expression	of	replicated	probes	were	averaged,	leaving	41,923	probes	that	622	 were	used	for	further	analysis.	Exploratory	principal	component	analysis	was	performed	623	
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with	the	prcomp	function	in	R.	Since	the	differences	between	the	cell	populations	were	624	 supposed	to	affect	only	a	relatively	small	subset	of	the	genes,	an	independent	filtering	625	 procedure	was	applied	to	exclude	the	probes	with	the	lowest	variance	across	all	samples,	626	 keeping	only	the	10%	most	variable	probes.	All	probes	were	standardized	by	subtracting	627	 the	mean	value	and	dividing	by	the	standard	deviation	across	all	samples	before	applying	628	 the	PCA.	We	extracted	the	top	50	probes	with	positive	and	negative	loadings,	respectively,	629	 on	the	first	principal	component	and	constructed	a	heatmap	of	their	expression	levels	630	 across	the	samples	(fig.	5C).	To	further	illustrate	the	similarities	between	samples	from	the	631	 different	cell	populations,	we	calculated	the	Euclidean	distance	between	all	pairs	of	632	 samples	along	the	first	principal	component.	The	distributions	of	pairwise	distances	633	 between	samples	from	each	pair	of	distinct	subgroups,	as	well	as	pairwise	distances	634	 between	samples	within	each	subgroup,	are	summarized	with	boxplots	in	fig.	5D	(”inter-635	 sample	distances”).	Differential	expression	analysis	was	performed	with	the	limma	R	636	 package	(version	3.20.8).	For	each	pair	of	cell	populations,	we	performed	a	gene-wise	637	 moderated	paired	t-test,	accounting	for	inter-donor	differences.	The	nominal	p-values	were	638	 adjusted	for	multiple	comparisons	using	the	Benjamini-Hochberg	procedure	(46).	639	 Hierarchical	clustering	was	performed	using	Euclidean	distance	and	complete	linkage.		640	
	641	
	642	
Proliferation	assays	and	in	vitro	stimulations.		643	 	644	 The	Complete	Medium	used	was	RPMI	1640,	complemented	with	10%	heat-inactivated	645	 FCS,	1%	non-essential	aminoacids	(Gibco),	1%	L-glutamine	(Gibco),	Hepes	(10mM)	and	646	 10’000	U/ml	of	penicillin/streptomycin	(Gibco).	For	the	proliferation	assays	using	NS4b	647	 peptide	and	cytokines,	PBMC	were	thawed	and	cultured	at	1.0-1.5	x	106	cells	per	ml	per	648	
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2cm2	in	flat-bottom	plates,	using	NS4b214-222	peptide	(LLWNGPMAV)	at	1	ug/ml,	human	IL-649	 2	at	100	U/ml	(Proleukin®,	Roche	Pharma)	and	recombinant	human	IL-15	at	20	U/ml	(10	650	 ng/ml,	Peprotech).	For	the	quantification	of	proliferation,	the	‘input	(counts	at	start)’	of	651	 A2/NS4b+	CD8	T	cells	was	calculated	based	on	the	number	of	PBMC	seeded	and	the	%	of	652	 A2/NS4b+	CD8	T	cells	determined	by	flow	cytometry.	The	‘counts	at	day	7’	were	quantified	653	 based	on	absolute	numbers	of	A2/NS4b+	CD8	T	cells	upon	full	acquisition	of	samples	by	654	 flow	cytometry.	The	‘expansion’	was	calculated	dividing	the	‘counts	at	day	7’	by	the	‘input’.		655	 For	the	expansion	of	purified	Naïve-like	or	Non-Naïve	YF-specific	CD8	T	cells,	A2/NS4b+	656	 CD8	T	cells	were	isolated	by	flow	cytometry	cell	sorting	(same	strategy	as	the	samples	used	657	 for	whole	transcriptome	analyses).	200	to	4’000	cells	(depending	on	the	donor’s	respective	658	 frequencies	of	A2/NS4b+	and	subsequent	Naïve-like/Non-Naïve	phenotype)	were	isolated	659	 and	stimulated	in	U-bottom	96-well	plates	with	1ug	/ml	PHA,	150	U/ml	IL-2	and	10e6/	ml	660	 “feeder”	cells.	These	“feeders”	were	prepared	by	mixing	freshly	prepared	PBMC	from	two	661	 independent	blood	donors,	irradiated	with	30Gy.	The	medium	composition	was	the	same	662	 as	above,	except	human	serum	was	used	instead	of	FCS.	Medium	was	renewed	and	cells	663	 were	split	periodically	until	sufficient	cells	had	expanded	to	allow	analysis	(cell	counting	to	664	 assess	population	doubling	and	flow	cytometry),	i.e.	at	day	14.	For	the	experiments	using	665	 anti-CD3	and	anti-CD28	stimulation	to	assess	short-term	function,	PBMC	were	first	thawed	666	 and	rested	overnight	in	complete	medium	(in	absence	of	cytokines)	at	a	density	of	0.75-1	x	667	 106	cells	per	cm2	per	0.5ml.	Next	day,	CD8	T	cells	were	enriched	using	the	negative	668	 selection	kit	from	StemCellTM	Technologies	(per	manufacturer’s	instructions).	Importantly,	669	 CD8	T	cells	were	stained	with	A2/NS4b	APC	tetramer	before	as	well	as	after	the	670	 stimulation	with	beads,	in	order	minimize	the	loss	of	detection	of	tetramer	positive	cells	671	 due	to	the	TCR	internalization	that	inherently	occurs	upon	T	cell	activation;	of	note,	this	672	 phenomenon	impacts	on	the	quality	of	the	tetramer	staining	following	T	cell	stimulation	673	
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and	renders	the	population	of	tetramer	positive	cells	less	distinct	as	opposed	to	ex-vivo	674	 analyses	(fig.	S5	F	and	S5	A:	activated,	versus	fig.	1A:	ex-vivo).	Tetramer-stained	CD8	T	cells	675	 were	plated	at	2.5x106	cells	per	2.5	ml	per	4cm2	(12-well	plate),	per	condition	and	676	 stimulated	with	anti-CD3	and	anti-CD28	beads	(Miltenyi	Biotec)	at	a	1:1	ratio.	For	the	677	 intracellular	cytokine	readout	at	4h,	Brefeldin	A	was	added	at	10ug/ml	(no	cytokines).	For	678	 the	readout	at	24h,	the	medium	was	supplemented	with	100	U/ml	IL-2.	679	 	680	 	681	
Quantifications	and	statistical	analysis.		682	 Quantifications	were	made	based	on	the	softwares	FlowJo,	Microsoft	Excel,	Graphpad	683	 Prism	and	SPICE	softwares.	Statistical	values	were	obtained	using	the	analyses	and	tests	684	 (including	normality	tests)	as	detailed	in	the	figure	legends;	where	indicated,	ns	=	not	685	 significant;	*	=	p	<0.05;	**	=	p	<0.01;	***	=	p	<0.001.	For	statistical	comparison	of	pie	charts	686	 generated	using	SPICE,	the	built-in	test	in	SPICE	software	(v5.3)	was	used	(using	10’000	687	 permutations)	(47).	688	 	689	 	690	
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Figure	legends:	879	 	880	
Fig.	1.	A2/NS4b+	CD8	T	cells	persist	long-term	after	YF	vaccination,	featuring	a	881	
Naïve-like	population.	41	vaccinees	were	studied,	covering	0.27	to	35	years	after	882	 vaccination	(table	S1).	Unvaccinated	donors	(UN,	n=10)	were	studied	as	controls.	A.	883	 Representative	flow	cytometry	plots	showing	A2/NS4b	tetramer	staining	of	total	CD8	T	884	 cells.	B.	Frequencies	of	A2/NS4b+	cells	within	Total	CD8	T	in	unvaccinated	controls	and	in	885	 vaccinees,	versus	years	since	vaccination.	Donors	below	0.01%	were	considered	negative.	886	 Symbols:	 	=	vaccinees	(n=34);	¢	=	vaccinees	with	multiple	vaccines	(n=4;	time	since	last	887	 vaccination	is	taken	into	account);	 	=	unvaccinated	controls	(UN,	n=3/10);	 	=	excluded	888	 donors:	vaccinees	(n=3/41)	or	UN	ctrls	(n=7/10).	Linear	regressions	correspond	to	the	889	 single-shot	vaccinees	group	( ),	indicating	R2	(goodness	of	fit)	and	95%	confidence	890	 intervals.	C.	Gating	strategy	to	discriminate	differentiation	subsets	based	on	the	891	 conventional	markers	CCR7	and	CD45RA,	as	indicated.	D.	Representative	flow	cytometry	892	 plots	showing	subsets	(CCR7	vs	CD45RA)	in	A2/NS4b+	CD8	T	cells	from	various	vaccinees.	893	
E.	Subset	distribution	(%)	within	A2/NS4b-specific	CD8	T	cells	across	vaccinees,	ordered	894	 vertically	with	increasing	‘years	since	vaccination’.	895	 	896	
Fig.	2.	The	Naïve-like	population	of	A2/NS4b+	CD8	T	cells	induced	by	the	Yellow	897	
Fever	17D	vaccine	is	stable	long-term.	A	and	B.	Quantification	of	the	frequency	of	898	 A2/NS4b+	cells	amongst	the	various	conventional	subsets,	showing	Naïve,	CM,	EM,	and	899	 EMRA	(A)	as	well	as	Naïvehigh	and	Naïveint	(B),	versus	increasing	‘years	since	vaccination’.	900	 Symbols:	¢	=	vaccinees	(n=34)	;	¢	=	vaccinees	with	multiple	vaccines	(n=4);	time	since	last	901	 vaccination	is	taken	into	account);	 	=	unvaccinated	controls	(UN,	n=3).	Linear	regressions	902	 shown	correspond	to	the	single-shot	vaccinees	group	( ),	with	details	on	R2	(goodness	of	903	
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fit),	line	and	95%	confidence	intervals.	C.		Compilation	of	the	slopes	with	standard	error	904	 from	the	linear	regressions	shown	in	A	and	B;	the	slope	reflects	the	trend	for	change	in	the	905	 LOG10	frequency	of	A2/NS4b+	cells	with	increasing	time	since	vaccination.	906	 	907	
Fig.	3.	Naïve-like	A2/NS4b+	CD8	T	cells	induced	by	the	YF	vaccine	are	clearly	distinct	908	
from	genuine	Naïve	cells	and	resemble	the	Tscm	subset.	A.	Representative	subset	909	 analysis	(CCR7	vs	CD45RA)	of	an	unvaccinated	donor,	within	A2/NS4b+	or	Total	CD8	T	910	 cells.	B.	Subset	distribution	in	A2/NS4b+	CD8	T	cells	from	unvaccinated	controls	(“UN”,	911	 n=5)	versus	vaccinees	(“VAC”,	n=16),	showing	mean	and	standard	error.	C	and	D.	The	912	 indicated	markers	were	compared	in	detectable	A2/NS4b+	subsets	in	unvaccinated	913	 controls	(n=3)	or	vaccinees	(n=16),	versus	the	reference	subsets	in	Total	CD8	T	cells.	914	 Shown	are	representative	off-set	overlay	histograms	(C)	and	corresponding	heat	map-915	 based	quantifications	of	%	positive	cells	(D)	with	Bonferroni	adjusted	p-values	following	2-916	 way	ANOVA	indicated	for	“UN”	vs	“VAC”.	E.	Representative	gating	of	the	Tscm	subset	as	917	 CD58+	CD95+	within	Total	Naïve	(CCR7+	CD45RA+)	cells.	F.	Frequency	of	A2/NS4b+	cells	918	 within	Total	Tscm	in	vaccinees	or	unvaccinated	controls	(mean	and	SD);	“n.d.”	=	not	919	 detectable.	G	and	H.	As	in	C	and	D,	for	18	markers	further	assessed	in	vaccinees	(n=16),	920	 with	Bonferroni	adjusted	p-values	following	2-way	ANOVA	indicated	per	marker.	Wilcoxon	921	 matched-pairs	test	to	compare	profiles	“overall”	are	indicated	at	the	bottom	922	 (complemented	in	fig.	S2).	923	 	924	
Fig.	4.	Comparison	of	A2/NS4b+	CD8	T	cells	to	other	antigen-specificities.	A.	A	925	 selection	of	16	vaccinees	(as	in	fig.	3)	was	analyzed	for	various	antigen-specific	populations	926	 based	on	two	combinatorial	tetramer	stainings,	including	Yellow	Fever	NS4b-specific	(*	=	927	 PE	in	staining	I,	PE	&	APC	in	staining	II),	EBV-specific	(A2/EBV-PE	in	staining	II),	Flu-928	
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specific	(A2/Flu-MA	APC	in	staining	II),	CMV-specific	(A2/NLV-	PE	and	–APC	in	staining	I)	929	 and	the	self-antigen	Melan-A-specific	(A2/ELA	APC	in	staining	I).	Total	CD8	T	cells	and	930	 antigen-specific	populations	were	analyzed	for	subset	distribution	(CCR7	vs	CD45RA),	and	931	 subsets	in	turn	for	CD58,	CD95	and	CXCR3.	One	representative	vaccinee	(positive	for	CMV)	932	 is	shown.	B.	Frequencies	of	antigen-specific	populations	in	the	16	vaccinees:	only	5	donors	933	 were	positive	for	CMV-specific	CD8	T	cells,	while	all	donors	showed	detectable	levels	of	934	 Melan-A-specific	CD8	T	cells	(fig.	S5).	C.	Subset	distribution	in	the	various	antigen-specific	935	 CD8	T	populations	across	donors	(mean	and	standard	error).	D.	Frequencies	of	cells	936	 positive	for	CD58,	CD95	and	CXCR3,	across	differentiation	subsets	within	the	various	937	 antigen-specificities	or	total	CD8	T	cells,	as	indicated.	938	 	939	
Fig.	5.	The	mRNA	profiles	of	Naïve-like	A2/NS4b+	CD8	T	cells	are	similar	to	Tscm	and	940	
display	highest	“Naïveness”.	Whole	genome	expression	profiles	were	assessed	on	the	five	941	 populations	shown	color-coded	in	A,	each	purified	from	n=8	vaccinees	(sorting	strategy	in	942	 fig.	S6).	B.	Sample	distribution	in	the	first	two	principal	components	(PC1	vs	PC2)	of	the	943	 Principal	Component	Analysis	(PCA)	considering	the	top	10%	most	variable	genes.	C.	944	 Heatmap-based	display	of	the	main	contributors	to	PC1	in	the	PCA	considering	the	top	10%	945	 variable	genes,	showing	the	40	samples	ordered	by	their	coordinate	on	PC1.	Note:	the	946	 corresponding	genes	are	listed	in	table	S2.	D	and	E.	Distribution	of	inter-sample	Euclidean	947	 distances	along	PC1	in	the	PCA	considering	the	top	10%	variable	genes.	Each	boxplot	948	 summarizes	the	pairwise	distances	between	samples	in	A2/NS4b+	Naïve-like	(left	panel)	949	 or	Total	Naïve	(right	panel)	versus	the	population	indicated	on	the	vertical	axis.	950	 	951	
Fig.	6.	Functional	characteristics	of	A2/NS4b+	CD8	T	cells:	responses	to	cognate	952	
peptide	and	homeostatic	IL-15,	and	self-renewal.	A	and	B.	PBMC	from	vaccinees	(n=35)	953	
		 41	
and	unvaccinated	controls	(n=3)	were	stimulated	with	NS4b	peptide	and	cytokines	(IL-2	or	954	 IL-15)	as	indicated,	for	7	days.	A:	expansion	based	on	fold	counts	to	start	(mean	and	SD;	955	 Wilcoxon	p-values	paired	per	vaccinee).	B:	expansion	versus	the	starting	frequency	of	956	 A2/NS4b+	CD8	T	cells	with	a	Naïve-like	phenotype.	Undetectable	samples	(<15	counts)	957	 were	excluded.	R	=	Spearman	correlations.	C	to	E.	Purified	A2/NS4b+	CD8	T	cells,	either	958	 Naïve-like	(n=5)	or	Non-Naïve	(n=4)	were	isolated	from	vaccinees	and	expanded	with	PHA,	959	 IL-2	and	irradiated	feeders	for	14	days.	C:	gating	strategy.	D:	frequencies	of	expanded	cells	960	 with	a	Naïve-like	phenotype,	showing	mean,	SD	and	p-value	from	Mann-Whitney	test.	E:	961	 population	doubling	of	Naïve-like	cells.	F.	CD8	T	cells	from	vaccinees	(n=7)	were	962	 stimulated	with	anti-CD3	and	anti-CD28	beads	for	24h.	Naïve-like	and	Non-Naïve	963	 A2/NS4b+	CD8	T	cells	were	analyzed	for	Ki67	and	HLA-DR	expression,	in	comparison	to	964	 the	reference	subsets	in	Total	CD8	T	(gating	shown	in	fig.	S5	F).	Shown	is	the	mean	and	SD;	965	 with	p-values	from	paired	Wilcoxon	tests.	966	 	967	
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Table	1.	Summary	of	the	CD8	T	cell	populations	referred	to	in	this	study.	969	
Population	 Subset	 CCR7	and	CD45RA	(6)	 Additional	markers:	
Total	Naive	 Conventional	Naive	(6)	 CCR7+	CD45RA+		(in	total	CD8	T)	
CD58-	CD95-	
CD28+	CD27+	
Total	Tscm	
Tscm;	recently	reported	subset:	"largely	
Naïve-like"	with	high	levels	of	certain	
markers	such	as	CD58	and	CD95	(23-25))	
CCR7+	CD45RA+		
(in	total	CD8	T)	
CD58+	CD95+	
CD28+	CD27+	
Total	CM	 Conventional	CM	(6)	 CCR7+	CD45RA-		(in	total	CD8	T)	
CD58+	CD95+	
CD28+	CD27+	
Total	EM	 Conventional	EM	(6)	 CCR7-	CD45RA-		(in	total	CD8	T)	
CD58+	CD95+	
CD28+/-	CD27+	
Total	EMRA	 Conventional	EMRA	(6)	 CCR7-	CD45RA+		(in	total	CD8	T)	
CD58+	CD95+	
CD28-	CD27-	
A2/NS4b+	Naive	in	
unvaccinated		
Naïve	(no	antigen	experience,		
i.e.	genuinely	Naive)	 CCR7+	CD45RA+	
CD58-	CD95-	
CD28+	CD27+	
A2/NS4b+		
Naive-like	
in	vaccinees	
Tscm	as	defined	by	markers;	with				
proximity	to	Conventional	Naïve	
("Naïveness")	in	terms	of	whole	
transcriptome	and	short-term	function	
CCR7+	CD45RA+;	can	be	
CCR7high	CD45RAhigh	
(Naive-high)	or	CCR7int	
CD45RAint	(Naïve-int)	
CD58+	CD95+	
CD28+	CD27+	
A2/NS4b+	EMRA												
in	vaccinees	
EMRA	with	particular	differences	(10,	13)	
such	as	high	levels	of	CD28,	CD27,	IL7Ra,	
CXCR3,	CD62L	and	BTLA	
CCR7-	CD45RA+	 CD58+	CD95+	CD28+/-	CD27+	
	970	 	971	 	972	
		
Fig.		
Fig.	S1.	Influence	of	inter-donor	and	age-related	variability	and	its	normalization	for	the	
study	of	A2/NS4b+	CD8	T	cell	subsets.	A.	“Years	since	vaccination”	versus	‘age	of	donors’:	donors	with	long	vaccination	history	(especially	>10	years)	tend	to	be	older.	Symbols:	 	=	vaccinees	(N=34);	 	=	unvaccinated	controls	(N=3);	 	=	excluded	donors	(%	A2/NS4b	<0.01%);		=	vaccinees	with	multiple	vaccines	(N=4).	R	=	Spearman	correlation	coefficient	on	the	‘vaccinees’	group.	B,	C	&	D.	For	the	vaccinees	group	(N=34),	the	age	of	donors	(x-axis)	was	plotted	against	the	%	of	various	differentiation	subsets	in	Total	CD8	T	cells	(C),	against	the	%	of	various	differentiation	subsets	in	A2/NS4b+	CD8	T	cells	(D),	and	against	the	%	of	A2/NS4b+	cells	within	the	various	differentiation	subsets	(E).	Spearman	correlations	R	and	best-fit	lines	are	indicated.	
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Fig.	S2.	Data	complementary	to	fig.	3.	A.	Subset	distribution	in	A2/NS4b+	CD8	T	cells	amongst	the	16	vaccinees	selected	for	in-depth	studies	(shown	is	the	average	and	standard	error	of	the	analyses	across	the	9	staining	panels	used	to	assess	the	31	markers).	B.	As	in	fig.	3	G	and	H,	with	additional	data:	a	total	of	31	markers,	showing	all	detectable	subsets	within	the	A2/NS4b	CD8	T	cells.	Cell	populations	below	20	events	were	not	considered	for	marker	analysis.	While	Naïve	and	EMRA	subsets	are	generally	predominant	(fig.	S2A),	not	all	donors	generated	data	for	all	populations.	Bonferroni	adjusted	p-values	following	2-way	ANOVA	are	indicated	per	marker.	Wilcoxon	matched-pairs	test	to	compare	profiles	“overall”	are	indicated	at	the	bottom.	C.	Expression	of	markers	in	the	Naïve-like	phenotype	of	YF-specific	CD8	T	cells	over	the	years	post-vaccination.	Shown	are	the	eight	markers	that	are	most	distinctly	expressed	in	Naïve-like	A2/NS4b+	CD8	T	cells	compared	to	Total	Naïve,	plotted	versus	the	‘years	since	vaccination’.	Spearman	correlations	R	and	best-fit	lines	are	indicated.	
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Fig.	S3.	Analyses	of	CD8	T	cells	specific	for	Yellow	Fever	epitopes	alternative	to	the	HLA-
A*02-restricted	NS4b.	CD8	T	cells	from	vaccinees	(n=27,	of	which	2	HLA-A*02	negative)	were	analyzed	for	specificities	alternative	to	HLA-A*02-restricted	NS4b214-222	(“A2/LLW”)	using	tetramers,	as	follows:	HLA-A*02/NS4a23-31	(“A2/AMD”,	n=25),	HLA-A*02/NS4a54-62	(“A2/VML”,	n=25),	HLA-A*02/ENV59-68	(“A2/VCY”,	n=25)	and	HLA-A*02/ENV347-355	(“A2/GIL”,	n=25);	and	non-HLA-A*02	restricted	epitopes:	HLA-A*24/NS1167-175	(“A24/VYM”,	n=1),	HLA-B*07/NS5211-219	(“B7/RPI”,	n=4),	HLA-B*35/NS2b110-118	(“B35/HPF”,	n=3).	A.	Frequencies	of	tetramer	positive	cells	in	total	CD8	T	cells;	the	frequencies	of	A2/NS4b+	CD8	T	cells	(n=25)	are	indicated	for	comparison.	The	threshold	for	positive	staining	was	0.01%.	B.	Gating	strategy	used	for	the	analysis	of	frequencies,	subset	distribution	and	staining	for	CD58,	CD95,	CXCR3,	CD28	and	CD27	of	tetramer	positive	cells,	showing	the	four	positive	samples	(two	A2/VML	and	two	B7/RPI	showed	tetramer	positive	>	0.01%).	
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Fig.	S4.	Data	complementary	to	fig.	5.	A	&	B.	Samples	and	sorting	strategy	for	the	purification	of	CD8	T	cell	subsets	for	mRNA	analysis	by	whole	genome	microarrays.	As	shown	in	A,	Naïve-like	YF-specific	CD8	T	cells	(population	1)	were	selected	within	total	CD8	T	cells	based	on	A2/NS4b+	cells	and	further	gating	on	CCR7+	CD45RA+	cells;	these	A2/NS4b+	Naïve-like	CD8	T	cells	were	checked	for	positive	CD58	and	CD95	expression,	in	contrast	to	the	conventional	Total	Naïve	population.	The	remaining	populations	were	isolated	from	total	live	CD8	T	cells	(A2/NS4b	tetramer	negative),	as	shown	in	B,	using	conventional	gating	to	select	for	Total	Naïve	(CCR7+	CD45RA+,	population	2),	Total	CM	(CCR7+	CD45RA-,	population	3)	and	Total	Effectors	(CCR7-,	population	4).	Lastly,	the	recently	described	Tscm	subset	was	isolated	from	the	conventional	Naïve	gate	(CCR7+	CD45RA+)	by	gating	on	the	CD58+	CD95+	cells	(population	5).	
C.	Subset	distribution	of	samples	from	the	eight	vaccinees	selected	(labeled	D1	to	D8	and	their	corresponding	study	number).	D.	Color-code	for	the	populations	shown	in	the	heatmaps	in	E	and	F.	E	and	F.	Unsupervised	clustering	of	the	40	samples	(5	populations,	n=8	donors)	by	interrogating	the	genesets	described	by	Gattinoni	et	al.	in	their	report	of	the	Tscm	subset	(23),	corresponding	to	the	“differentially	regulated	genes	among	CD8	T+	cell	subsets”	(“Differentiation”,	in	G)	and	to	the	differentially	regulated	genes	among	Tscm	and	Naïve	(“Tscm	
versus	Naïve”,	in	H).	The	degree	of	clustering	and	relatedness	between	samples	is	represented	by	the	branching	shown	above	the	heatmap.		
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Fig.	S5.	Data	complementary	to	fig.	6.	A.	‘Expansion’	(data	shown	in	fig.	6A:	peptide	+	cytokines)	related	to	the	‘years	since	vaccination’.	R	=	Spearmann	correlation	coefficients.	B	to	
E.	Data	complementary	to	the	expansion	of	purified	A2/NS4b+	CD8	T	cells,	Naïve-like	or	Non-Naïve,	at	day	14	(fig.	6	C	to	E).	B:	representative	flow	cytometry	analyses	of	expanded	cells.	C:	Total	population	doubling	(mean,	SD,	and	p-value	from	Mann-Whitney	test).	D:	Subset	distribution	in	expanded	cells	(mean,	SEM,	and	p-values	from	2-way	ANOVA).	E.	Frequency	of	positive	cells	amongst	the	various	subsets	in	expanded	cells,	for	the	three	indicated	markers	(mean	and	SEM).	F.	Gating	strategy	for	the	analyses	of	CD8	T	cells	stimulated	with	anti-CD3	and	anti-CD28	(fig.	6	F).	Reference	subsets	were	gated	as	in	fig.	1	C;	Tscm	were	gated	as	CD58+	CD95+	in	the	Naïve	gate	(note	that	the	24h	stimulation	resulted	in	upregulated	CD95,	as	compared	to	unstimulated	or	4h	stimulation	in	fig.	S6).	NS4b-specific	CD8	T	cell	subsets	were	gated	as	A2/NS4b+	and	subsequent	CCR7	and	CD45RA	discrimination,	as	indicated.	The	various	populations	were	then	assessed	for	Ki-67	and	HLA-DR	expression.	
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Fig.	S6.	Cytokine	production	by	NS4b-specific	CD8	T	cell	subsets	in	comparison	the	
reference	subsets	in	Total	CD8	T	cells.	CD8	T	cells	from	vaccinees	(n=7)	were	stimulated	with	anti-CD3	and	anti-CD28	beads	for	4h.	A.	Gating	strategy:	the	reference	subsets	were	gated	as	aforementioned	(fig.	1	C);	Tscm	were	gated	based	on	CD58+	CD95+	expression	in	the	Naïve	gate;	A2/NS4b+	CD8	T	cell	subsets	(Naïve	or	Non-Naïve)	were	gated	based	A2/NS4b+	signal	and	subsequent	CCR7	and	CD45RA	discrimination,	as	indicated.	B.	Representative	plots	of	the	various	populations	assessed	for	intracellular	cytokine	production,	including	IFNγ,	IL-2	and	TNFα.	C.	Quantification	of	co-expression	of	cytokines	(SPICE	analysis),	showing	one	pie	chart	with	the	average	cytokine	production	per	population	and	per	treatment.	Pie	arcs	and	slices	represent	the	percentage	of	cells	positive	for	IFNγ,	IL-2	and	TNFα,	as	indicated	in	the	legend.		
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Table	S1.	Summary	of	the	cohort	of	Yellow	Fever	17D	vaccinees.	Study	identification	code	(LAU),	age,	gender,	vaccination	history	(years)	and	frequencies	of	A2/NS4b+	in	total	CD8	T	cells	(donors	in	regular	italic	had	frequencies	below	0.01%).	
	
	 	
LAU Age Sex Years since vaccine
% A2/NS4b 
in CD8 T
5051 35.6 F 0.27 0.2030
5052 24.2 F 0.49 0.3650
5019 31.0 F 0.63 0.1390
5044 51.4 F 0.71 0.2510
5013 30.38 M 1.24 0.0703
5046 60.8 M 1.43 0.0492
5040 23.0 M 2.21 0.0447
5009 50.9 F 2.38 0.0399
5050 23.2 F 2.39 0.4150
5031 25.41 F 2.39 0.0638
5039 24.4 M 2.82 0.0200
5035 22.5 F 3.53 0.0483
5003 25.9 F 4.05 0.1750
5018 24.9 M 4.60 0.2020
5025 27.78 F 5.56 0.0485
5006 37.60 F 5.75 0.3230
5020 49.4 M 6.09 0.0084
5042 24.0 F 6.67 0.0192
5001 26.76 F 7.20 0.0266
5012 29.5 F 7.68 0.0309
5048 33.56 M 7.89 0.0301
5066 49.9 M 8.21 0.065
5058 30.71 F 8.66 0.0621
5057 25.75 F 9.82 0.0280
5014 21.6 F 10.21 0.0132
5036 21.0 F 10.26 0.0113
5033 23.57 F 12.10 0.0228
5067 34.8 M 12.43 0.074
5022 41.44 M 12.69 0.0458
5043 70.1 M 13.42 0.1560
5032 51.1 M 14.27 0.0141
5029 26.6 M 17.79 0.0280
5047 31.6 F 19.46 0.0014
5002 42.4 M 20.88 0.0178
5028 61.4 F 21.16 0.0333
5045 46.7 M 27.84 0.0141
5041 55.5 M 35.02 0.0076
5026 57.5 F 8.32.(34.05) 0.0119
5015 58.5 F 9.81.(22.05) 0.0133
5023 59.3 M 14.17.(25.47,.
38.26)
0.0111
5024 61.0 M 16.61.(31.33) 0.0368
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Table	S2.	Main	genes	contributing	to	PC1.	Main	positive	and	negative	contributors	in	the	PCA	considering	the	top	10%	variable	genes.	
	 	
Probe Gene Probe Gene
A)23)P105957 ACTN1 )A)33)P3243832) ZEB2
A)23)P343398 CCR7 )A)24)P53976) GLUL
A)33)P3334398 CA6 )A)23)P207564) CCL4
A)19)P00802168 AK123124 )A)33)P3363933) FCRL6
A)21)P0012873 LOC100507387 )A)33)P3354607) CCL4
A)32)P84373 FAM153A )A)23)P151294) IFNG
A)33)P3307253 AK5 )A)23)P99275) KLRB1
A)24)P213788 LOC641518 )A)24)P261760) KLRG1
A)21)P0007821 XLOC)009661 )A)23)P142560) ZEB2
A)23)P30634 BACH2 )A)23)P107744) S1PR5
A)23)P255896 C2orf89 )A)33)P3285734) FCRL6
A)21)P0000787 LOC100507387 )A)19)P00322571) MIAT
A)33)P3308512 SLC16A10 )A)24)P129632) DLG5
A)24)P108863 SCML1 )A)23)P209678) PLEK
A)23)P411723 PLAG1 )A)23)P103803) FCRL3
A)21)P0000788 LOC100507387 )A)21)P0000590) ZEB2
A)21)P0014082 LOC100507013 )A)23)P68601) CST7
A)33)P3280801 LMO7 )A)24)P173754) C1orf21
A)24)P143492 BCAS4 )A)23)P119042) NKG7
A)21)P0008352 XLOC)010859 )A)24)P268676) BHLHE40
A)23)P214627 AIF1 )A)33)P3346891) MYBL1
A)23)P8834 EPHX2 )A)33)P3209096) CD58
A)24)P20630 LEF1 )A)33)P3327200) ATP2B4
A)21)P0008483 XLOC)011117 )A)33)P3251369) GAB3
A)24)P85243 FAM153A )A)23)P1473) PRF1
A)21)P0014850 LOC100507427 )A)24)P408740) CMC1
A)21)P0008484 XLOC)011117 )A)19)P00318175) MIAT
A)23)P10025 NELL2 )A)33)P3368334) FCRL3
A)23)P34375 TCEA3 )A)23)P142447) MYO1F
A)23)P147465 PARK2 )A)23)P146644) ANXA2
A)23)P80503 ROBO1 )A)21)P0014596) LOC100506291
A)21)P0008385 XLOC)010924 )A)24)P323114) ANXA2P3
A)33)P3344504 APBA2 )A)24)P69095) ENC1
A)21)P0008486 XLOC)011117 )A)33)P3879161) PIK3AP1
A)23)P120281 EDAR )A)24)P204244) ANXA2P1
A)21)P0008485 XLOC)011117 )A)23)P204208) KLRD1
A)21)P0012276 SLC25A15 )A)24)P233786) FAM129A
A)24)P30923 SNN )A)23)P124108) ITGAM
A)33)P3280805 LMO7 )A)24)P54174) TNFRSF1B
A)24)P944253 KLHL6 )A)21)P0000059) APOBEC3H
A)23)P149375 THEM4 )A)33)P3354589) ENST00000378350
A)23)P78742 FLT3LG )A)33)P3342056) TIGIT
A)23)P56703 C2orf89 )A)33)P3354604) ENST00000400702
A)32)P19806 DNAH11 )A)23)P213562) F2R
A)24)P248053 TOP1MT )A)33)P3672482) USP28
A)24)P376760 CA6 )A)23)P209954) GNLY
A)23)P138717 RGS10 )A)21)P0014838) LOC100505471
A)33)P3329356 ENST00000512129 )A)33)P3235213) TIGIT
A)21)P0000171 IL6R )A)33)P3274501) KLRF1
A)33)P3358731 PCSK5 )A)33)P3376821) GZMA
PC1:%positive PC1:%negative
PCA%with%Top%10%%(Figure%S6%A)
	
Table	S3.	Differentially	expressed	genes	comparing	Naïve-like	A2/NS4b+	CD8	T	cells	to	
the	other	four	subsets	listed.	Adjusted	p	value	=	0.05	(blue)	and	=	0.1	(orange).	
Large	table	à	provided	as	a	separate	excel	file.	
	
	
	
	
Table	S4.	Tetramers	and	antibodies	used	for	Flow	Cytometry	analyses.	A)	Tetramers	
Tetramer	
HLA	
peptide	
context	
sequence	 protein	
HLA-A*0201	
LLWNGPMAV	 NS4b214-222	
Yellow	Fever	virus	
AMDTISVFL	 NS4a23-31	VMLFILAGL	 NS4a54-62		VCYNAVLTHV	 ENV59-68	GILVTVNPI	 ENV347-355	
HLA-A*2402	 VYMDAVFEY	 NS1167-175	
HLA-B*0701	 RPIDDRFGL	 NS5211-219	
HLA-B*3501	 HPFALLLVL	 NS2b110-118	
HLA-A*0201	
ELAGIGILTV	 Melan-A26-35(A27L)	 Melanoma	GIGLGFVFTL	 Matrix58-66	 Influenza	GLCTLVAML	 BMLF1280-288		 Epstein	Barr	Virus	NLVPMVATV	 pp65495-503	 Cytomegalovirus	
All	tetramers	were	purchased	from	TCmetrix	Sarl	(Epalinges,	Switzerland).	
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B)	Antibodies	
Target	 Fluorochrome	 clone	 Company	 Staining	
CD8	 APC-Alexa750	 B9.11	 Beckman	Coulter	
surface	
CCR7	 Brilliant	Violet	or	PE-Cy7	 G043H7	 Biolegend	CD45RA	 ECD	 2H4LD11LDB9	 Beckman	Coulter	
		 Alexa700	 HI100	 BD	Biosciences	CD16	 Krome	Orange	 3G8	 Beckman	Coulter	
CD27	 FITC	 M-T271	 BD	Biosciences	
		 APC-eF780	 O323	 eBioscience	
CD28	 APC	 CD28.2	 BD	Biosciences	IL-7Ra/CD127	 PerCP-Cy5.5	 HCD127	 Biolegend	CD62L	 PerCP-Cy5.5	 DREG-56	 Biolegend	CD45RO	 Alexa700	 UCHL1	 Biolegend	ABC-B1/CD243	 PE	 UIC2	 eBioscience	FAS/CD95	 PE-Cy7	 DX2	 Biolegend	CD58	 FITC	or	PE	 1C3	 BD	Biosciences	CD11a	 PE-Cy7	 HI111	 BD	Biosciences	CD103	 PE-Cy7	 Ber-ACT8	 Biolegend	CLA	 PE	 HECA-452	 Miltynei	Biotec	IL-2Rb/CD122	 PE	 Mik-B2	 BD	Biosciences	IL-15Ra/CD215	 PE	 JM7A4	 Biolegend	IL-18Ra/CD218a	 PE	 444	 Biolegend	IL-2Ra/CD25	 PE-Cy7	 BC96	 Biolegend	CD38	 Alexa700	 HIT2	 eBioscience	CD69	 FITC	 FN50	 BD	Biosciences	HLA-DR	 FITC	or	PerCP-Cy5.5	 L243	 Biolegend	ICOS	 FITC	 C398.4A	 Biolegend	PD1	 PerCP-eF710	 eBioJ105	 eBioscience	PDL1	 PE-Cy7	 MIH1	 eBioscience	2B4	 PE-Cy5.5	 C1.7	 Biolegend	KLRG1	 A488	 13F12F2	 in	house	(H.	Pircher)	BTLA	 PE-Cy7	 BTLA7.2	 Beckman	Coulter	CD161	 PE-Cy7	 HP-3G10	 Biolegend	CCR4	 PerCP-Cy5.5	 TG6	 Biolegend	CCR5	 PerCP-Cy5.5	 HEK/1/85a	 Biolegend	CXCR3	 PerCP-Cy5.5	 G025H7	 Biolegend	Ki-67	 PE	 Ki-67	 Biolegend	IFNg	 PE	 4S.B3	 BD	Biosciences	
intracellular	IL-2	 PerCP-Cy5.5	 MQ1-17H12	 BD	Biosciences	TNFa	 Alexa700	 HIT2	 eBioscience	Granzyme	A		 Alexa700	 CB9	 Biolegend	Granzyme	B	 ECD	 GB11	 Molecular	Probes	Perforin	 FITC	 dG9	 Ancell	
	
